Literature DB >> 29020632

Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors.

Sampada Kalan1, Ramon Amat1, Miriam Merzel Schachter1, Nicholas Kwiatkowski2, Brian J Abraham3, Yanke Liang2, Tinghu Zhang2, Calla M Olson2, Stéphane Larochelle1, Richard A Young4, Nathanael S Gray2, Robert P Fisher5.   

Abstract

Cdk7, the CDK-activating kinase and transcription factor IIH component, is a target of inhibitors that kill cancer cells by exploiting tumor-specific transcriptional dependencies. However, whereas selective inhibition of analog-sensitive (AS) Cdk7 in colon cancer-derived cells arrests division and disrupts transcription, it does not by itself trigger apoptosis efficiently. Here, we show that p53 activation by 5-fluorouracil or nutlin-3 synergizes with a reversible Cdk7as inhibitor to induce cell death. Synthetic lethality was recapitulated with covalent inhibitors of wild-type Cdk7, THZ1, or the more selective YKL-1-116. The effects were allele specific; a CDK7as mutation conferred both sensitivity to bulky adenine analogs and resistance to covalent inhibitors. Non-transformed colon epithelial cells were resistant to these combinations, as were cancer-derived cells with p53-inactivating mutations. Apoptosis was dependent on death receptor DR5, a p53 transcriptional target whose expression was refractory to Cdk7 inhibition. Therefore, p53 activation induces transcriptional dependency to sensitize cancer cells to Cdk7 inhibition.
Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  5-fluorouracil; CDK inhibitor; Cdk7; apoptosis; chemical genetics; colon cancer; nutlin-3; p53; synthetic lethality; transcription

Mesh:

Substances:

Year:  2017        PMID: 29020632      PMCID: PMC5687273          DOI: 10.1016/j.celrep.2017.09.056

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  51 in total

1.  Three RNA polymerase II carboxyl-terminal domain kinases display distinct substrate preferences.

Authors:  Y Ramanathan; S M Rajpara; S M Reza; E Lees; S Shuman; M B Mathews; T Pe'ery
Journal:  J Biol Chem       Date:  2001-01-16       Impact factor: 5.157

2.  Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells.

Authors:  Stéphane Larochelle; Karl A Merrick; Marie-Emilie Terret; Lara Wohlbold; Nora M Barboza; Chao Zhang; Kevan M Shokat; Prasad V Jallepalli; Robert P Fisher
Journal:  Mol Cell       Date:  2007-03-23       Impact factor: 17.970

3.  Design of allele-specific inhibitors to probe protein kinase signaling.

Authors:  A C Bishop; K Shah; Y Liu; L Witucki; C Kung; K M Shokat
Journal:  Curr Biol       Date:  1998-02-26       Impact factor: 10.834

4.  Super-enhancers in the control of cell identity and disease.

Authors:  Denes Hnisz; Brian J Abraham; Tong Ihn Lee; Ashley Lau; Violaine Saint-André; Alla A Sigova; Heather A Hoke; Richard A Young
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

5.  A New Bliss Independence Model to Analyze Drug Combination Data.

Authors:  Wei Zhao; Kris Sachsenmeier; Lanju Zhang; Erin Sult; Robert E Hollingsworth; Harry Yang
Journal:  J Biomol Screen       Date:  2014-02-03

6.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

7.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

8.  CDK7-dependent transcriptional addiction in triple-negative breast cancer.

Authors:  Yubao Wang; Tinghu Zhang; Nicholas Kwiatkowski; Brian J Abraham; Tong Ihn Lee; Shaozhen Xie; Haluk Yuzugullu; Thanh Von; Heyuan Li; Ziao Lin; Daniel G Stover; Elgene Lim; Zhigang C Wang; J Dirk Iglehart; Richard A Young; Nathanael S Gray; Jean J Zhao
Journal:  Cell       Date:  2015-09-24       Impact factor: 41.582

9.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.

Authors:  N S Gray; L Wodicka; A M Thunnissen; T C Norman; S Kwon; F H Espinoza; D O Morgan; G Barnes; S LeClerc; L Meijer; S H Kim; D J Lockhart; P G Schultz
Journal:  Science       Date:  1998-07-24       Impact factor: 47.728

10.  Chemical genetics reveals a specific requirement for Cdk2 activity in the DNA damage response and identifies Nbs1 as a Cdk2 substrate in human cells.

Authors:  Lara Wohlbold; Karl A Merrick; Saurav De; Ramon Amat; Jun Hyun Kim; Stéphane Larochelle; Jasmina J Allen; Chao Zhang; Kevan M Shokat; John H J Petrini; Robert P Fisher
Journal:  PLoS Genet       Date:  2012-08-23       Impact factor: 5.917

View more
  27 in total

1.  Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment.

Authors:  Weiwei Shan; Jiao Yuan; Zhongyi Hu; Junjie Jiang; Yueying Wang; Nicki Loo; Lingling Fan; Zhaoqing Tang; Tianli Zhang; Mu Xu; Yutian Pan; Jiaqi Lu; Meixiao Long; Janos L Tanyi; Kathleen T Montone; Yi Fan; Xiaowen Hu; Youyou Zhang; Lin Zhang
Journal:  Cell Rep       Date:  2020-07-14       Impact factor: 9.423

Review 2.  Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors.

Authors:  Pabitra K Parua; Robert P Fisher
Journal:  Nat Chem Biol       Date:  2020-06-22       Impact factor: 15.040

3.  Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype.

Authors:  Calla M Olson; Yanke Liang; Alan Leggett; Woojun D Park; Lianbo Li; Caitlin E Mills; Selma Z Elsarrag; Scott B Ficarro; Tinghu Zhang; Robert Düster; Matthias Geyer; Taebo Sim; Jarrod A Marto; Peter K Sorger; Ken D Westover; Charles Y Lin; Nicholas Kwiatkowski; Nathanael S Gray
Journal:  Cell Chem Biol       Date:  2019-03-21       Impact factor: 8.116

4.  A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer.

Authors:  Jason A Somarelli; Roham Salman Roghani; Ali Sanjari Moghaddam; Beatrice C Thomas; Gabrielle Rupprecht; Kathryn E Ware; Erdem Altunel; John B Mantyh; So Young Kim; Shannon J McCall; Xiling Shen; Christopher R Mantyh; David S Hsu
Journal:  Mol Cancer Ther       Date:  2020-11-06       Impact factor: 6.261

5.  MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53.

Authors:  John Hines; Schan Lartigue; Hanqing Dong; Yimin Qian; Craig M Crews
Journal:  Cancer Res       Date:  2018-11-01       Impact factor: 12.701

6.  Taking Aim at Glycolysis with CDK8 Inhibitors.

Authors:  Robert P Fisher
Journal:  Trends Endocrinol Metab       Date:  2018-02-20       Impact factor: 12.015

7.  CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer.

Authors:  Jihye Kim; Young-Jae Cho; Ji-Yoon Ryu; Ilseon Hwang; Hee Dong Han; Hyung Jun Ahn; Woo Young Kim; Hanbyoul Cho; Joon-Yong Chung; Stephen M Hewitt; Jae-Hoon Kim; Byoung-Gie Kim; Duk-Soo Bae; Chel Hun Choi; Jeong-Won Lee
Journal:  Gynecol Oncol       Date:  2019-11-24       Impact factor: 5.482

8.  Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition.

Authors:  Jingyu Peng; Ming Yang; Ran Bi; Yueyuan Wang; Chunxi Wang; Xue Wei; Zhihao Zhang; Xiao Xie; Wei Wei
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

Review 9.  Targeting the transcription cycle and RNA processing in cancer treatment.

Authors:  Lin Zhang; Youyou Zhang; Xiaowen Hu
Journal:  Curr Opin Pharmacol       Date:  2021-05-05       Impact factor: 4.768

Review 10.  Advancements in chemical biology targeting the kinases and phosphatases of RNA polymerase II-mediated transcription.

Authors:  Wantae Kim; Blase LeBlanc; Wendy L Matthews; Zhong-Yin Zhang; Yan Zhang
Journal:  Curr Opin Chem Biol       Date:  2021-03-11       Impact factor: 8.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.